Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Brentuximab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05316246
What this trial is testing

Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

Who this might be right for
NK/T Cell Lymphoma Nos
Shanghai Zhongshan Hospital 40
Not applicableWithdrawnNCT06104878
What this trial is testing

A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Who this might be right for
Hodgkin Lymphoma
Takeda
Early research (Phase 1)Study completedNCT01060904
What this trial is testing

Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Who this might be right for
Disease, Hodgkin
Seagen Inc. 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT01703949
What this trial is testing

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Who this might be right for
Recurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Hodgkin Lymphoma+1 more
University of Washington 28
Testing effectiveness (Phase 2)Study completedNCT00866047
What this trial is testing

Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

Who this might be right for
Lymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
Seagen Inc. 58
Testing effectiveness (Phase 2)WithdrawnNCT04138875
What this trial is testing

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Who this might be right for
PTLDLymphoid TumorHematopoietic/Lymphoid Cancer+6 more
Yale University
Testing effectiveness (Phase 2)UnknownNCT02098512
What this trial is testing

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Who this might be right for
Hodgkin Lymphoma
New York Medical College 20
Testing effectiveness (Phase 2)Study completedNCT01461538
What this trial is testing

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Who this might be right for
Acute Lymphoid LeukemiaAcute Myeloid LeukemiaAnemia, Refractory, With Excess of Blasts+1 more
Seagen Inc. 84
Testing effectiveness (Phase 2)Ended earlyNCT02988843
What this trial is testing

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Who this might be right for
Germ Cell Tumor
Masonic Cancer Center, University of Minnesota 1
Early research (Phase 1)WithdrawnNCT05244473
What this trial is testing

A Safety Study of Brentuximab Vedotin in Participants With HIV

Who this might be right for
Human Immunodeficiency Virus
Seagen Inc.
Early research (Phase 1)Ended earlyNCT01900496
What this trial is testing

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Who this might be right for
Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 6
Testing effectiveness (Phase 2)WithdrawnNCT04795869
What this trial is testing

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Who this might be right for
Recurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular T-Cell Lymphoma+11 more
Northwestern University
Testing effectiveness (Phase 2)WithdrawnNCT01620229
What this trial is testing

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Hematopoietic/Lymphoid Cancer
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT04569032
What this trial is testing

Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Who this might be right for
Peripheral T-cell Lymphoma
Seagen, a wholly owned subsidiary of Pfizer 82
Testing effectiveness (Phase 2)Active Not RecruitingNCT03233347
What this trial is testing

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Who this might be right for
Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin Lymphoma+4 more
Academic and Community Cancer Research United 83
Testing effectiveness (Phase 2)Active Not RecruitingNCT02734771
What this trial is testing

Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Patrick Reagan 24
Testing effectiveness (Phase 2)Study completedNCT02581631
What this trial is testing

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Who this might be right for
Non-Hodgkin's Disease
Bristol-Myers Squibb 145
Testing effectiveness (Phase 2)Study completedNCT01771107
What this trial is testing

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

Who this might be right for
AIDS-Related Hodgkin LymphomaAnn Arbor Stage II Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin Lymphoma+9 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Study completedNCT01421667
What this trial is testing

Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, B-CellLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin+1 more
Seagen Inc. 176
Testing effectiveness (Phase 2)Active Not RecruitingNCT01896999
What this trial is testing

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
National Cancer Institute (NCI) 146
Next Page